UNSPSC 51172145: Pimetremide

This classification denotes an antispasmotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VY58MWL7J. European Medicines Agency schedules Pimetremide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09842MIG. Pimetremide generally arises in the molecular formula C16H18N2O2.

UNSPSC 51172145 Pimetremide is a Commodity code that captures pharmaceutical testing and specimen analysis services as actually procured by state and local criminal justice and corrections agencies. The code sees activity in drug screening and confirmation testing for offender monitoring programs, where state and local jurisdictions contract for immunoassay screening, LC/MS/MS or GC/MS confirmation testing, and alternative specimen collection methodologies (oral fluid, hair) to support community supervision and corrections operations. Issuing bodies under this code include county corrections and community supervision departments operating pretrial, probation, and parole monitoring programs. Testing volumes run into the tens of thousands of tests annually per jurisdiction, with per-test pricing models and multi-year contract terms typical of the work.

Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 in September 2026 for offender specimen collection and drug testing services, with a response deadline of July 23, 2026 at 2:00 p.m. and an estimated contract value of $600,000 over two years with optional renewals through five years total. The scope includes staffing two collection sites (Plano and McKinney) during business hours and selected Saturdays, operating an Interactive Voice Response notification system for randomized testing, performing screening and confirmation testing across five- and six-panel protocols, and offering hair and oral fluid alternatives. The vendor must hold SAMHSA, Texas DPS, or CAP lab certification. Pricing is submitted per-test on three models (screening only, confirmation after screening, and screening with automatic confirmation), with no surcharges permitted and price redetermination limited to annual cost-of-living adjustments capped at 3.0 percent. Evaluation weights vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional phase-two demonstrations and interviews (up to 30 additional points). The anticipated award date is August 10, 2026.